Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

2.28

Margin Of Safety %

22

Put/Call OI Ratio

0.72

EPS Next Q Diff

0.97

EPS Last/This Y

3.62

EPS This/Next Y

0.64

Price

133.12

Target Price

169.93

Analyst Recom

2.08

Performance Q

-11.47

Relative Volume

0.65

Beta

0.15

Ticker: BIIB




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-08BIIB118.380.921.6587402
2025-05-09BIIB118.150.930.1388372
2025-05-12BIIB124.60.920.4687596
2025-05-13BIIB123.20.906.7987592
2025-05-14BIIB120.470.930.7889384
2025-05-15BIIB123.720.921.7389857
2025-05-16BIIB125.570.910.0889753
2025-05-19BIIB129.460.790.1891808
2025-05-20BIIB130.520.740.3895488
2025-05-21BIIB127.140.740.1295574
2025-05-22BIIB126.290.741.1996280
2025-05-23BIIB125.820.730.4496647
2025-05-27BIIB128.070.730.3695194
2025-05-28BIIB127.530.732.5996133
2025-05-29BIIB132.750.730.2296650
2025-05-30BIIB129.710.720.2297679
2025-06-02BIIB131.20.720.6897180
2025-06-03BIIB131.90.720.6297764
2025-06-04BIIB131.860.720.3198942
2025-06-05BIIB130.380.720.3599349
2025-06-06BIIB133.140.720.1199996
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-08BIIB118.39-22.8383.814.84
2025-05-09BIIB118.10-22.9359.814.86
2025-05-12BIIB124.40-22.9465.414.86
2025-05-13BIIB123.18-22.9345.614.86
2025-05-14BIIB120.46-22.9322.314.86
2025-05-15BIIB123.68-22.9417.314.86
2025-05-16BIIB125.68-22.9395.414.86
2025-05-19BIIB129.44-22.9423.914.86
2025-05-20BIIB130.51-22.9380.614.85
2025-05-21BIIB126.76-22.9308.014.85
2025-05-22BIIB126.29-22.9356.414.85
2025-05-23BIIB125.84-22.9357.514.84
2025-05-27BIIB128.39-22.9404.214.84
2025-05-28BIIB127.55-22.9351.814.84
2025-05-29BIIB132.71-23.1443.214.83
2025-05-30BIIB129.79-23.1321.014.83
2025-06-02BIIB131.12-23.1384.414.83
2025-06-03BIIB131.84-23.1374.914.83
2025-06-04BIIB131.86-23.1364.814.83
2025-06-05BIIB130.36-23.1342.414.83
2025-06-06BIIB133.12-23.1405.814.83
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-08BIIB-1.010.332.36
2025-05-09BIIB-1.010.332.36
2025-05-12BIIB-1.01-0.622.18
2025-05-13BIIB-1.01-0.622.18
2025-05-14BIIB-1.01-0.622.18
2025-05-15BIIB-1.01-0.622.18
2025-05-16BIIB-1.01-0.622.18
2025-05-19BIIB-0.990.822.18
2025-05-20BIIB-4.390.822.18
2025-05-21BIIB-4.390.822.18
2025-05-22BIIB-4.390.822.18
2025-05-23BIIB-4.390.822.18
2025-05-27BIIB-4.39-1.652.18
2025-05-28BIIB-4.39-1.652.28
2025-05-29BIIB-4.39-1.652.28
2025-05-30BIIB-4.39-1.652.28
2025-06-02BIIB-4.39-1.402.28
2025-06-03BIIB-4.39-1.402.28
2025-06-04BIIB-4.39-1.402.28
2025-06-05BIIB-4.39-1.402.28
2025-06-06BIIB-4.39-1.402.28
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

3.02

Avg. EPS Est. Current Quarter

4.06

Avg. EPS Est. Next Quarter

3.99

Insider Transactions

-4.39

Institutional Transactions

-1.4

Beta

0.15

Average Sales Estimate Current Quarter

2324

Average Sales Estimate Next Quarter

2278

Fair Value

163.06

Quality Score

90

Growth Score

58

Sentiment Score

40

Actual DrawDown %

71.6

Max Drawdown 5-Year %

-72.7

Target Price

169.93

P/E

13.15

Forward P/E

8.63

PEG

P/S

2.07

P/B

1.15

P/Free Cash Flow

8.01

EPS

10.13

Average EPS Est. Cur. Y​

14.83

EPS Next Y. (Est.)

15.47

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

15.73

Relative Volume

0.65

Return on Equity vs Sector %

-15.3

Return on Equity vs Industry %

-23.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.19

EBIT Estimation

405.8
Biogen Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 7605
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
stock quote shares BIIB – Biogen Inc. Stock Price stock today
news today BIIB – Biogen Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BIIB – Biogen Inc. yahoo finance google finance
stock history BIIB – Biogen Inc. invest stock market
stock prices BIIB premarket after hours
ticker BIIB fair value insiders trading